MARKET

ZVSA

ZVSA

ZyVersa Therapeutics Inc
OTCMQB
0.230
+0.030
+15.00%
Closed 15:27 03/31 EDT
OPEN
0.205
PREV CLOSE
0.200
HIGH
0.230
LOW
0.200
VOLUME
23.75K
TURNOVER
4.97K
52 WEEK HIGH
1.940
52 WEEK LOW
0.110
MARKET CAP
1.86M
P/E (TTM)
-0.0516
1D
5D
1M
3M
1Y
5Y
1D
ZyVersa Therapeutics GAAP EPS of -$4.18
Seeking Alpha · 2h ago
ZYVERSA THERAPEUTICS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 3h ago
ZyVersa FY25 net loss more than doubled to $25 million
Reuters · 3h ago
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Barchart · 8h ago
Weekly Report: what happened at ZVSA last week (0323-0327)?
Weekly Report · 1d ago
Weekly Report: what happened at ZVSA last week (0316-0320)?
Weekly Report · 03/23 10:12
Weekly Report: what happened at ZVSA last week (0309-0313)?
Weekly Report · 03/16 10:12
Weekly Report: what happened at ZVSA last week (0302-0306)?
Weekly Report · 03/09 10:12
More
About ZVSA
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.

Webull offers Zyversa Therapeutics Inc stock information, including OTCMQB: ZVSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVSA stock methods without spending real money on the virtual paper trading platform.